Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

Withdrawn

• Conditions: Abscess, Intra-Abdominal; Cholecystitis; Wound Infections; Peritonitis; Appendicitis

• Registration Number: NCT00463762
• Lead Sponsor: Pfizer

Brief Summary

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-04-17
• Study First Submitted QC: 2007-04-19
• Study First Posted: 2007-04-20
• Study Start: 2007-05
• Status Verified: 2011-04
• Last Update Submitted: 2011-04-21
• Last Update Posted: 2011-04-22

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Male or female patient of age 18 years or older.
• Patient with intraabdominal/hepatobiliary infection.?

Read More

Exclusion Criteria

• Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified